Han Shaoqin, Huang Jianyun, Liu Bingqian, Xing Bowen, Bordeleau Francois, Reinhart-King Cynthia A, Li Wenxin, Zhang J Jillian, Huang Xin-Yun
College of Life Sciences, Wuhan University, Wuhan, China; Department of Physiology and Biophysics, Cornell University, Weill Medical College, New York, NY 10065, USA.
Department of Physiology and Biophysics, Cornell University, Weill Medical College, New York, NY 10065, USA.
Mol Oncol. 2016 Aug;10(7):966-80. doi: 10.1016/j.molonc.2016.03.006. Epub 2016 Apr 1.
Tumor metastasis is the major cause of mortality of cancer patients, being responsible for ∼90% of all cancer deaths. One of the key steps during tumor metastasis is tumor cell migration which requires actin cytoskeletal reorganization. Among the critical actin cytoskeletal protrusion structures are antenna-like filopodia. Fascin protein is the main actin-bundling protein in filopodia. Here we report the development of fascin-specific small-molecules that inhibit the interaction between fascin and actin. These inhibitors block the in vitro actin-binding and actin-bundling activities of fascin, tumor cell migration and tumor metastasis in mouse models. Mechanistically, these inhibitors likely occupy one of the actin-binding sites, reduce the binding of actin filaments, and thus lead to the inhibition of the bundling activity of fascin. At the cellular level, these inhibitors impair actin cytoskeletal reorganization. Our data indicate that target-specific anti-fascin agents will have great potential for treating metastatic tumors.
肿瘤转移是癌症患者死亡的主要原因,约占所有癌症死亡人数的90%。肿瘤转移过程中的关键步骤之一是肿瘤细胞迁移,这需要肌动蛋白细胞骨架的重组。在关键的肌动蛋白细胞骨架突出结构中,有天线样丝状伪足。Fascin蛋白是丝状伪足中主要的肌动蛋白捆绑蛋白。在此,我们报告了抑制Fascin与肌动蛋白相互作用的Fascin特异性小分子的研发情况。这些抑制剂在小鼠模型中阻断了Fascin的体外肌动蛋白结合和肌动蛋白捆绑活性、肿瘤细胞迁移及肿瘤转移。从机制上讲,这些抑制剂可能占据了一个肌动蛋白结合位点,减少了肌动蛋白丝的结合,从而导致Fascin捆绑活性的抑制。在细胞水平上,这些抑制剂损害了肌动蛋白细胞骨架的重组。我们的数据表明,靶向特异性抗Fascin药物在治疗转移性肿瘤方面具有巨大潜力。